Peregrine Pharmaceuticals Announces Third Quarter Financial Results

Peregrine Pharmaceuticals, Inc., a biopharmaceutical company with a broad portfolio of products under development, announced financial results for the third quarter ended Jan. 31, 2005. The company reported a net loss of $3,744,000 or $0.03 per share, basic and diluted, for the quarter ended Jan. 31, 2005. This compares to a net loss of $4,137,000 or $0.03 per share, basic and diluted, for the same period last year.

Big News Network (http://feeds.bignewsnetwork.com/redir.php?jid=da510a28e21f29bb&cat=6dcd932030878143)